FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	DС	20549
rvasiliigion,	D.C.	20040

OMB APPROVAL										
OMB Number: 3235-0										
Estimated average burden										
hours per response	e: 0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Goldberg Mark Alan					2. Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc. [ IMGN ]									ck all app	tionship of Reporting Po all applicable) Director		on(s) to Iss		
(Last)	(Fir	est) (N	/liddle)			3. Date of Earliest Transaction (Month/Day/Year) 12/29/2023								Office below	er (give title		Other (s below)	pecify	
C/O IMMUNOGEN, INC. 830 WINTER STREET					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person					
(Street) WALTHAM MA 02451					Form filed by More than One Reporting Person										orting				
(City)	(St	ate) (Z	<u>Z</u> ip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										ded to				
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired	, Dis	posed of	, or E	Bene	ficiall	y Own	ed			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day					y/Year) Execut		ution Date,				es Acquired (A) o Of (D) (Instr. 3, 4 a				ties cially Following	6. Own Form: I (D) or I (I) (Inst	Direct of ndirect in the contract of the contr	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										v	Amount	(A) or (D)		Price	Transa	Reported Transaction(s) (Instr. 3 and 4)			
Common	Stock			12/29/2	2023			A		569	<b>A</b> (	1) {	\$29.65	60,720		Ι			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, ecurity or Exercise (Month/Day/Year) if any		4. Transaction Code (Instr. 8)		of Deriv	r osed ) r. 3, 4	Expiration Da		ite	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		De Se (Ir	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y Ov Fo Dii or (I)	wnership orm: rect (D) Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code V		(A)	(D)	Date Exercisable		Expiration Date	Title	Amo or Num of Shar	ber					

## **Explanation of Responses:**

1. Shares of common stock issued pursuant to the Compensation Policy for Non-Employee Directors as amended June 14, 2023 in lieu of cash compensation for services performed for the quarter ended December 31, 2023.

/s/ Renee Lentini, Attorney-in-01/03/2024

**Fact** 

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.